The main activity in the laboratory is the synthesis and purification of peptides for the following aims:

Selective targeting of drugs with HSV-1 gD derived peptides:

Based on the entry mechanism of Herpes simplex virus (HSV) we design peptides selectively entering into fibroblasts, epithelial cells and neurons. The HSV peptides internatizing efficiently and selectively are conjugated with drugs against intracellular pathogens.

Complement activating peptides for the selective elimination of autoreactive B-cells:

We are preparing the complement activating sequences of the HIV gp120 glycoprotein, which - conjugating to the epitopes of autoreactive B-cells via nanoparticles - are able to selectively eliminate the B-cell population with the given selectivity.